The influence of Apolipoprotein E genotype on regional pathology in Alzheimer's disease

BMC Neurology

Volumn 13, Issue , 2013, Pages

  Sabbagh, Marwan N ^a   Malek Ahmadi, Michael ^a   Dugger, Brittany N ^a   Lee, Katarina ^a   Sue, Lucia I ^a   Serrano, Geidy ^a   Walker, Douglas G ^a   Davis, Kathryn ^a   Jacobson, Sandra A ^a   Beach, Thomas G ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; ENTORHINAL CORTEX; FEMALE; FRONTAL CORTEX; GENE FREQUENCY; GENOTYPE; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PARIETAL CORTEX; PROSPECTIVE STUDY; SCORING SYSTEM; TEMPORAL CORTEX;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; BRAIN; FEMALE; GENOTYPE; HUMANS; MALE; NEUROFIBRILLARY TANGLES; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 84877276546     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-13-44     Document Type: Article

References (32)

1. Nagy Z, Esirir MM, Jobst KA, Johnston C, Litchfield S, Sim E, Smith AD. Influence of the Apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neuroscience 1995, 69(3):757-761. 10.1016/0306-4522(95)00331-C, 8596645.
2. Ohm TG, Kirca M, Bohl J, Scharnagl H, Grob W, Marz W. Apolipoprotein E polymorphism influences not only cerebral senile plaque load but also Alzheimer-type neurofibrillary tangle formation. Neuroscience 1995, 66(3):583-587. 10.1016/0306-4522(94)00596-W, 7644022.
3. Caselli RJ, Walker D, Sue L, Sabbagh M, Beach T. Amyloid load in nondemented brains correlates with APOE e4. Neurosci Lett 2010, 473(3):168-171. 10.1016/j.neulet.2010.02.016, 2851172, 20153809.
4. Raber J, Huang Y, Ashford JW. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging 2004, 25(5):641-650. 10.1016/j.neurobiolaging.2003.12.023, 15172743.
5. Corder E, Saunders A, Strittmatter W, Schmechel D, Gaskell P, Small G, Roses A, Haines J, Pericak-Vance M. Gene dose of Apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261(5123):921-923. 10.1126/science.8346443, 8346443.
6. DeMattos RB. Apolipoprotein E dose-dependent modulation of β-amyloid deposition in a transgenic mouse model of Alzheimer's disease. J Mol Neurosci 2004, 23(3):255-262. 10.1385/JMN:23:3:255, 15181254.
7. Crutcher KA. Apolipoprotein E is a prime suspect, not just an accomplice, in Alzheimer's disease. J Mol Neurosci 2004, 23(3):181-188. 10.1385/JMN:23:3:181, 15181246.
8. Verghese PB, Castellano JM, Holtzman DM. Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol 2011, 10(3):241-252. 10.1016/S1474-4422(10)70325-2, 3132088, 21349439.
9. Fullerton SM, Clark AG, Weiss KM, Nickerson DA, Taylor SL, Stengard JH, Salomaa V, Vartiainen E, Perola M, Boerwinkle E, Sing CF. Apolipoprotein E variation at the sequence haplotype level: implications for the origin and maintenance of a major human polymorphism. Am J Hum Genet 2000, 67(4):881-900. 10.1086/303070, 1287893, 10986041.
10. Saunders AM, Strittmatter WJ, Schmechal D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ, Hulette C, Crain B, Goldgaber D, Roses AD. Association of Apolipoprotein E allele ε{lunate}4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993, 43(8):1467-1472. 10.1212/WNL.43.8.1467, 8350998.
11. Beffert U, Cohn JS, Petit-Turcotte C, Tremblay M, Aumont N, Ramassamy C, Davignon J, Poirier J. Apolipoprotein E and β-amyloid Levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and Apolipoprotein E genotype dependent. Brain Res 1999, 843(1-2):87-94.
12. Thal DR, Udo R, Orantes M, Braak H. Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology 2002, 58(12):1791-1800. 10.1212/WNL.58.12.1791, 12084879.
13. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991, 82(4):239-259. 10.1007/BF00308809, 1759558.
14. Beach TG, Sue LI, Walker DG. The Sun health research institute brain donation program: description and experience, 1987-2007. Cell Tissue Bank 2008, 9(3):229-245. 10.1007/s10561-008-9067-2, 2493521, 18347928.
15. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1987, Washington DC: American Psychiatric Press, 4, American Psychiatric Association.
16. The National Institute on aging, and Reagan Institute Working Group on diagnostic criteria for the Neuropathological Assessment of Alzheimer's Disease Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol Aging 1997, 18(4 Suppl):S1-S2. The National Institute on aging, and Reagan Institute Working Group on diagnostic criteria for the Neuropathological Assessment of Alzheimer's Disease.
17. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L. The consortium to establish a registry for Alzheimer's disease (CERAD). part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41(4):479-486. 10.1212/WNL.41.4.479, 2011243.
18. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990, 31(3):545-548.
19. Murray ME, Graff-Radford N, Ross OA, Petersen RC, Duara R, Dickson DW. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol 2011, 10(9):785-796. 10.1016/S1474-4422(11)70156-9, 3175379, 21802369.
20. Dickerson BC, Wolk DA, the Alzheimer's Disease Neuroimaging Initiative Dysexecutive versus amnesic phenotypes of very mild Alzheimer's disease are associated with distinct clinical, genetic and cortical thinning characteristics. J Neurol Neurosurg Psychiatry 2011, 82(1):45-51. 10.1136/jnnp.2009.199505, 3023235, 20562467, the Alzheimer's Disease Neuroimaging Initiative.
21. van der Flier WM, Schoonenboom SWM, Pijnenburg YAL, Fox NC, Sheltens P. The effect of APOE genotype on clinical phenotype in Alzheimer disease. Neurology 2006, 67(3):526-527. 10.1212/01.wnl.0000228222.17111.2a, 16894123.
22. Pl R, Siedlak SI, Smith MA, Perry G. Apolipoprotein E interaction with the neurofibrillary tangles and senile plaques in Alzheimer disease: implications for disease pathogenesis. Biochem Biophys Res Commun 1995, 208(2):657-663. 10.1006/bbrc.1995.1389, 7695621.
23. Ignatius MJ, Gebicke-Harter PJ, Skene JHP, Schilling JW, Weisgraber KH, Mahley RW, Shooter EM. Expression of Apolipoprotein E during nerve degeneration and regeneration. Proc Natl Acad Sci USA 1986, 83(4):1125-1129. 10.1073/pnas.83.4.1125, 323024, 2419900.
24. Wisniewski T, Castano EM, Golabek A, Vogel T, Frangione B. Acceleration of Alzheimer's fibril formation by Apolipoprotein E in vitro. Am J Pathol 1994, 145(5):1030-1035. 1887417, 7977635.
25. Wisniewski T, Lalowski M, Golabek B, Frangione B, Vogel T. Is Alzheimer's disease an Apolipoprotein E amyloidosis?. Lancet 1995, 345(8955):956-958. 10.1016/S0140-6736(95)90701-7, 7715296.
26. Holtzman DM, Herz J, Bu G. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med 2012, 2(3):a006312. 10.1101/cshperspect.a006312, 3282491, 22393530.
27. Jiang Q, Lee CYD, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tonotonoz P, Landreth GE. ApoE promotes the proteolytic degradation of Aβ. Neuron 2008, 58(5):681-693. 10.1016/j.neuron.2008.04.010, 2493297, 18549781.
28. Guo L, LaDu MJ, Van Eldik LJ. A dual role for apolipoprotein E in neuroinflammation: anti- and pro-inflammatory activity. J Mol Neurosci 2004, 23(3):205-212. 10.1385/JMN:23:3:205, 15181248.
29. Griffin WST, Sheng JG, Royston MC, Gentleman SM, McKenzie JE, Graham DI, Roberts GW, Mrak RE. Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. Brain Pathol 1998, 8(1):65-72.
30. Baum L, Chen L, Nq HK, Pang CP. Apolipoprotein E isoforms in Alzheimer's disease pathology and etiology. Microsc Res Tech 2000, 50(4):278-281. 10.1002/1097-0029(20000815)50:4<278::AID-JEMT5>3.0.CO;2-T, 10936880.
31. Schiefermeier M, Kollegger H, Madl C, Schwarz C, Holzer M, Kofler J, Sterz F. Apolipoprotein E polymorphism: survival and neurological outcome after cardiopulmonary resuscitation. Stroke 2000, 31(9):2068-2073. 10.1161/01.STR.31.9.2068, 10978031.
32. Ward A, Crean S, Mercaldi CJ, Collins JM, Boyd D, Cook MN, Arrighi HM. Prevalence of apolipoprotein e4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer's disease: a systematic review and meta-analysis. Neuroepidemiology 2012, 38(1):1-17. 10.1159/000334607, 22179327.